Abstract

This study provides a safe and low-cost in-house protocol for RT-qPCR-based detection of SARS-CoV-2 using mouthwash–saliva self-collected specimens to achieve clinical and epidemiological surveillance in a real-time web environment applied to ambulatory populations. The in-house protocol comprises a mouthwash–saliva self-collected specimen, heat virus inactivation, and primers to target virus N-gene region and the human RPP30-gene. Aligning with 209 SARS-CoV-2 sequences confirmed specificity including the Alpha variant from the UK. Development, validation, and statistical comparison with official nasopharyngeal swabbing RT-qPCR test were conducted with 115 specimens of ambulatory volunteers. A web–mobile application platform was developed to integrate a real-time epidemiological and clinical core baseline database with mouthwash–saliva RT-qPCR testing. Nine built-in algorithms were generated for decision-making on testing, confining, monitoring, and self-reports to family, social, and work environments. Epidemiological and clinical follow-up and SARS-CoV-2 testing generated a database of 37,351 entries allowing individual decision-making for prevention. Mouthwash–saliva had higher sensitivity than nasopharyngeal swabbing in detecting asymptomatic and mild symptomatic cases with 720 viral copy number (VCN)/mL as the detection limit (Ct = 37.6). Cycling threshold and viral loading were marginally different (p = 0.057) between asymptomatic (35 Ct ± 2.8; 21,767.7 VCN/mL, range 720–77,278) and symptomatic (31.3 Ct ± 4.5; 747,294.3 VCN/mL, range 1433.6–3.08 × 106). We provided proof-of-concept evidence of effective surveillance to target asymptomatic and moderate symptomatic ambulatory individuals based on integrating a bio-safety level II laboratory, self-collected, low-risk, low-cost detection protocol, and a real-time digital monitoring system. Mouthwash–saliva was effective for SARS-CoV-2 sampling for the first time at the community level.

Highlights

  • SARS-CoV-2 detection protocols were developed soon after the COVID-19 outbreak on 31 December 2019 [1,2,3]

  • In contrast to 45 nasopharyngeal swabs (NPS) sampling, self-collected MWS was successfully done without pain, sneezing, or coughing in 70 individuals distributed in three wide age-range ambulatory cohorts, including one symptomatic 81-year-old male and 3- and 5-year-old asymptomatic children (Table 1, Figure 1)

  • Slight discomfort was observed in a few cases, with throat pain requiring 2–3 pauses to complete the rinse period

Read more

Summary

Introduction

SARS-CoV-2 detection protocols were developed soon after the COVID-19 outbreak on 31 December 2019 [1,2,3]. The main focus was to achieve sensitivity and specificity to discriminate SARS-CoV-2 from other respiratory viruses using RT-qPCR assays [1,3]. Further protocols, based on nasopharyngeal and/or oropharyngeal (NPS/OPS) swabs and sputum specimens, adhere to the same principles using up to four gene targets and even more.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call